Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

MeiraGTx Holdings Q3 2026 Results: Net Loss of $51.2M, Loss Widens

MeiraGTx reported a significant increase in total revenue to $326.5 million for the nine months ended September 30, 2026, primarily driven by license and service revenue from related parties. This resulted in a net income of $63.1 million for the period, compared to a net loss of $129.3 million in the prior year, despite a net loss in the third quarter of 2026.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue4.80.4
Net income-51.2-50.5
EPS (diluted, $ a share)$-0.53$-0.62

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+1074.1%
Source

10-Q filed with the SEC, NASDAQ: MGTX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

MeiraGTx Holdings plc: key numbers

Share price
$8.46Close, Nov 17
Market cap
$827M
Shares outstanding
97.73MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from MeiraGTx Holdings plc

All →
8:08 AM ET 8-K
Financial Results

MeiraGTx Holdings Financial Results

MeiraGTx reported third quarter 2026 financial results and provided a regulatory update for its lead candidate bota-vec, with an MAA submission to the EMA expected in December 2026 and a BLA submission to the FDA in Q1 2027. The company is preparing for a potential commercial launch of bota-vec for XLRP in late 2027 while advancing its Phase 2 AQUAx2 study for radiation-induced xerostomia.

“We are pleased to report that we have now completed much of the work towards submission of full global regulatory filings with the EMA and FDA for bota-vec for the treatment of XLRP. The MAA dossier is complete and awaiting submission and the BLA is expected to follow early next year.”

Alexandria Forbes, Ph.D., president and chief executive officer of MeiraGTx

“We are actively preparing for our pivotal Phase 2 AQUAx2 12-month data readout for the treatment of radiation-induced xerostomia in mid-2027. As we progress these two lead programs through filing for potential approval and commercialization, we are also advancing several programs towards IND.”

Alexandria Forbes, Ph.D., president and chief executive officer of MeiraGTx
8:57 PM ET Form 4
Insider Selling

MeiraGTx Holdings CFO & COO Richard Giroux Sells $557K of Stock

Richard Giroux, CFO & COO, sold 56,000 shares of MeiraGTx Holdings plc at $9.95 a share, worth $557K in total on Oct 20, 2026. Shares held after the trade: 852,530 (-6.2%).

Value
$557K
Shares
56,000
Price
$9.95
Role
CFO & COO
Holding change
-6.2%
Trade date
Oct 20, 2026
8:53 PM ET Form 4
Insider Selling

MeiraGTx Holdings Chief Sci Ofcr, Ophthalmology Stuart Naylor Sells $294K of Stock

Stuart Naylor, Chief Sci Ofcr, Ophthalmology, sold 27,659 shares of MeiraGTx Holdings plc at $10.64 a share, worth $294K in total on Oct 6, 2026. Shares held after the trade: 613,187 (-4.3%).

Value
$294K
Shares
27,659
Price
$10.64
Role
Chief Sci Ofcr, Ophthalmology
Holding change
-4.3%
Trade date
Oct 6, 2026
8:13 AM ET 8-K
Leadership Change

MeiraGTx Holdings Leadership Change

MeiraGTx Holdings plc appointed Alan M. Sebulsky to its Board of Directors as a Class I director, effective September 23, 2026. Mr. Sebulsky, a veteran healthcare portfolio manager with over 40 years of experience, will also serve on the company's Science and Technology Committee.

Counterparty
Alan M. Sebulsky

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.